




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Cook, G. J. R., Azad, G. K., Taylor, B. P., Lee, E., Morrison, M. S., Hughes, S., ... Goh, V. (2018). Imaging v3
integrin expression in skeletal metastases with 99mTc-maraciclatide Single-Photon Emission Computed
Tomography: Detection and therapy response assessment. European journal of nuclear medicine and molecular
imaging. DOI: 10.1007/s00259-017-3926-7
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 28. Feb. 2018
ORIGINAL ARTICLE
Imaging αvβ3 integrin expression in skeletal metastases
with 99mTc-maraciclatide single-photon emission computed
tomography: detection and therapy response assessment
Gary J. R. Cook1,2 & Gurdip K. Azad1 & Benjamin P. Taylor3 & Eugene Lee2 & Matthew S. Morrison4 & Simon Hughes3 &
Stephen Morris3 & Sarah Rudman3 & Simon Chowdhury3 & Vicky Goh1
Received: 10 October 2017 /Accepted: 27 December 2017
# The Author(s) 2018. This article is an open access publication
Abstract
Purpose Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target.
This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targetingαvβ3 integrin, occurs in
prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy.
Methods The study group comprised 17 men with bone-predominant metastatic PCa who underwent whole-body planar and
single-photon emission computed tomography/computed tomography (SPECT/CT) imaging with 99mTc-maraciclatide before
(n = 17) and 12 weeks after (n = 11) starting treatment with abiraterone. Tumour to normal bone (T:N) ratios, tumour to muscle
(T:M) ratios and CT Hounsfield units (HU) were measured in up to five target metastases in each subject. An oncologist blinded
to study scans assessed clinical responses up to 24 weeks using conventional criteria.
Results Before treatment, metastases showed specific 99mTc-maraciclatide accumulation (mean planar T:N and T:M ratios 1.43
and 3.06; SPECT T:N and T:M ratios 3.1 and 5.19, respectively). Baseline sclerotic lesions (389–740 HU) showed lower T:M
ratios (4.22 vs. 7.04, p = 0.02) than less sclerotic/lytic lesions (46–381 HU). Patients with progressive disease (PD; n = 5) showed
increased planar T:N and T:M ratios (0.29 and 12.1%, respectively) and SPECT T:N and T:M ratios (11.9 and 20.2%, respec-
tively). Patients without progression showed decreased planar T:N and T:M ratios (0.27 and −8.0%, p = 1.0 and 0.044, respec-
tively) and SPECT T:N and T:M ratios (−21.9, and −27.2%, p = 0.3 and 0.036, respectively). The percentage change in CT HU
was inversely correlated with the percentage change in SPECT T:M ratios (r = −0.59, p = 0.006).
Conclusions 99mTc-maraciclatide accumulates in PCa bone metastases in keeping with increased αvβ3 integrin expression.
Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar
and SPECT T:M ratios after 12 weeks of treatment differed between patients with and without PD and 99mTc-maraciclatide
imaging may be a potential method for assessing early response.
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Introduction
Skeletal metastases are common in patients with prostate
cancer (PCa) and are associated with significant morbidity
and skeletal-related events [1]. However, effective systemic
treatment is available leading to improvements in overall
survival of several months to years [2]. This is longer than
in most other types of cancer that have metastasized to the
skeleton, and the management of PCa bone metastases
therefore has a significant impact on healthcare resources
[3]. It is recognized that conventional imaging, including
99mTc-diphosphonate bone scintigraphy or computed
tomography (CT), is poor at determining treatment response
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or nonresponse at an early time point when patients can
undergo therapeutic transition to second-line therapy that
may be more effective, and can be saved from side effects of
ineffective treatments [4, 5].
Whilst bone metastases from PCa are predominantly oste-
oblastic in nature, leading to sclerotic radiological morpholo-
gy, it is known that they also demonstrate increased osteoclast
activity that may be a major contributor to morbidity (e.g.
pathological fracture) and which may be a therapeutic target
for drugs including RANK ligand inhibitors (e.g. denosumab)
and osteoclast inhibitors (e.g. bisphosphonates), that can de-
crease skeletal-related events [2]. Osteoclast activity is there-
fore a relevant process in the pathophysiology of bone metas-
tases and may provide a useful target for detection and re-
sponse assessment by imaging probes. Osteoclasts express
higher levels of the αvβ3 integrin than any other cell types
in the body [6] and this integrin heterodimer is involved in the
adhesion of osteoclasts to the bone matrix [7]. It strongly
binds the Arg-Gly-Asp (RGD) motif, which when
radiolabelled, has been used to successfully image αvβ3
integrin expression related to osteoclast activity in animal
models [8, 9]. 99mTc-Maraciclatide (99mTc-NC100692) is a
cyclic peptide with a RGD binding site with high affinity for
the αvβ3 integrin in vitro and in vivo, and has been investi-
gated for detection of αvβ3 integrin overexpression in angio-
genesis [10, 11].
In this study our hypotheses were that 99mTc-maraciclatide
specifically accumulates in PCa bone metastases and that
changes in uptake correlate with treatment response to system-
ic therapy. Our aims were to measure uptake of 99mTc-
maraciclatide in patients with de-novo or progressive bone
metastases from PCa, to correlate uptake and changes in up-
take with CT density (Hounsfield units, HU), as a surrogate
for the underlying osteoblastic and osteoclastic activity, and to
determine if changes in uptake at 12 weeks could act as a
marker of treatment response.
Materials and methods
The study group comprised 17 consecutive men (mean age
73.4 years) with de-novo or progressive bone-predominant
metastatic PCa scheduled for treatment with abiraterone.
Informed consent was obtained from all individual partici-
pants included in the study. Ethical and radiation committee
(ARSAC) approvals were obtained for the study. Six patients
did not undergo 12-week imaging, in two due to patient choice
and in four due to lack of tracer availability. In 11 patients who
had follow-up 99mTc-maraciclatide imaging at 12 weeks, a
clinical oncologist blinded to the 99mTc-maraciclatide imaging
defined the clinical response to abiraterone using conventional
clinical (including pain score), biochemical (prostate-specific
antigen, alkaline phosphatase) and imaging results (CT and
bone scan) up to 24 weeks after the start of therapy. Clinical
response was recorded as progressive disease (PD) or non-PD,
i.e. stable disease, partial response or complete response.
Patients underwent whole-body planar scintigraphy 45min
after injection of 740 MBq 99mTc-maraciclatide using a dual-
headed gamma camera (Philips, Cleveland, OH) with low-
energy high-resolution collimators and a 20% energy window
centred on 140 keV, before and 12 weeks after starting
abiraterone. An additional single-photon emission CT/CT
(SPECT/CT) scan of a target lesion was then acquired. The
acquisition parameters for the SPECT component were 20 s/
frame and 128 projections over 360° and the images were
reconstructed with an ordered subsets expectation maximiza-
tion algorithm with five iterations over eight subsets. The ac-
quisition parameters for the CT component were 100 mAs/
slice, 120 kV, pitch 1.188 and rotation time 0.75 s.
Regions of interest (ROI) were drawn manually around up
to five target lesions per patient on anterior and posterior planar
scans to calculate the geometric mean activity. If a lesion could
only be visualized on either the anterior or the posterior view,
then only this ROI was used for subsequent analysis. A contra-
lateral ROI of the same area was placed over a normal area of
bone and if the lesion was in the midline, e.g. the spine, then the
nearest normal midline vertebra was used to define an area of
normal skeletal uptake. A tumour to normal bone (T:N) ratio
was calculated for each metastasis. ROIs were also placed over
muscle in the right lateral thigh to calculate a geometric mean
muscle activity and hence a tumour to muscle (T:M) ratio. For
SPECT imaging T:N and T:M ratios were calculated for each of
the five lesions within the field of view with counts averaged
for all the slices in which tumour activity was visible. For
muscle activity the erector spinae muscle was used when the
lateral thigh was not in the field of view. The same lesions were
analysed in the 11 patients who had 12-week scans and the
mean percentage change in each 99mTc-maraciclatide uptake
ratio was also recorded. Mean CT HU were recorded for each
lesion on the corresponding CT component of the SPECT/CT
acquisition on pretreatment and 12-week scans. No attempt was
made to measure an index of global skeletal involvement as
previously reported for bone scintigraphy [12], as planar T:N
ratios and normal skeletal uptake are lower than those from
standard bone scintigraphy, precluding this approach.
Changes in uptake ratios were compared between patients
with clinical PD and those with non-PD and the significance
of differences in uptake ratios and in percentage change in
uptake ratios between those below and above the median
baseline CT HU value and between those below and above
the median percentage change in CT HU, respectively, were
evaluated using Student’s t test or the Mann-Whitney U test
depending on whether or not the data were normally distrib-
uted as tested by the Shapiro-Wilk test. Spearman’s test was
used to determine correlations between percentage change in
CT HU and percentage change in 99mTc-maraciclatide uptake.
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Statistical tests were performed with IBM SPSS Statistics,
version 24.
Results
In the 11 patients who underwent baseline and 12-week imaging,
the clinical reference standard indicated PD in five patients and
non-PD in six patients (stable disease in five, treatment response
in one). There was no significant difference in percentage change
in serum calcium or alkaline phosphatase levels between those
with PD (2.4% and 23.6%, respectively) and those with non-PD
(−0.7% and 10.4%, respectively). Metastatic bone lesions
showed accumulation of 99mTc-maraciclatide with mean planar
T:N and T:M ratios of 1.43 (± 0.27) and 3.06 (± 0.83), respec-
tively, and SPECT T:N and T:M ratios of 3.1 (± 1.7) and 5.19 (±
2.77), respectively, before treatment in the 17 patients (Fig. 1). In
these scans, the most sclerotic lesions (389–740 HU, mean 583
HU) showed lower 99mTc-maraciclatide T:M ratios (4.22 vs.
7.04, p = 0.02) than the less sclerotic or lytic lesions (46–381
HU, mean 223 HU; Fig. 2).
Five patients with PD showed a mean percentage increase
in planar T:N and T:M ratios and SPECT T:N and T:M ratios
(0.29, 12.1, 11.9 and 20.2%, respectively) whereas six patients
with non-PD showed no change or a reduction in T:M ratios
(0.27, −8.0, −21.9, −27.2%, respectively; Fig. 3). Changes in
planar and SPECT T:M ratios were significantly different be-
tween patients with PD and those with non-PD (p = 0.044 and
0.036, respectively) whereas changes in T:N ratios were not
significantly different (p = 1.0 and 0.3, respectively).
Percentage change in CT HU in individual lesions between
baseline and 12 weeks showed an inverse correlation with
percentage change in SPECT T:M ratios (r = −0.59, p =
0.006). Percentage change in SPECT T:M ratios in lesions
with an increase in CT HU (5.8% to 290.9%) were signifi-
cantly different from those with a decrease in CT HU (−7.9 to
−67.1%) with median percentage changes of −30.9% and
3.9%, respectively (p = 0.016).
Discussion
This study showed that 99mTc-maraciclatide, a tracer that is
known to target the αvβ3 integrin [10], specifically
Fig. 1 a 99mTc-maraciclatide posterior planar image (left) shows uptake
in a sacral metastasis (arrows; T:N ratio 1.81, T:M ratio 4.79) that is also
demonstrated on the 99mTc-methylene diphosphonate bone scan (right). b
99mTc-maraciclatide uptake is visible on the axial SPECT image (top) and
the fused SPECT/CT image (bottom; T:N ratio 8.0, T:M ratio 10.0), and is
visible on the CT bone windows (centre; HU = 381)
Fig. 2 Axial SPECT image (top) and axial fused SPECT/CT image
(bottom) show 99mTc-maraciclatide uptake in a left scapula metastasis
(T:N ratio 8.25, T:M ratio 5.91) that appears lytic on the CT image
(centre; HU = 46)
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accumulates in metastatic bone lesions in patients with PCa.
The uptake of 99mTc-maraciclatide (SPECT T:M ratio) was
higher in the untreated lowest density bone metastases than in
those with higher density, as measured by CT HU, suggesting
that uptake is related to the degree of osteoclast activity.
Previous in vitro experiments with an alternative positron emis-
sion tomography (PET) αvβ3 integrin targeting tracer,
64Cu-
CB-TE2A-c(RGDyK), have shown specific uptake in osteo-
clasts and a correlation with osteoclast numbers in a mouse
model of parathyroid hormone-induced osteolysis in the
calvaria [8]. Similarly, the same PET tracer has shown specific
uptake in a mouse model of osteolytic bone metastases [9], and
a different PET tracer, 68Ga-DOTA-E-[c(RGDfK)]2, has shown
specific accumulation in a rat model of breast cancer bone
metastasis [13]. In humans, a different 99mTc-RGD tracer
(99mTc-3PRGD2) has been shown to detect bone metastases
from lung cancer with high sensitivity and with better specific-
ity than 99mTc-methylene diphosphonate scintigraphy [14]. A
PET tracer, 18F-galacto-RGD, has been found to accumulate in
metastatic PCa with a T:M ratio of 2.8 ± 1.3 leading to the
detection of 58 out of 74 metastases in 12 patients [15].
In our study, patients who had clinical PD by 24 weeks
showed significantly different percentage changes in planar
and SPECT T:M ratios at 12 weeks (12.1% and 20.2% in-
creases, respectively) compared with those with non-PD
(−8.0% and −27.2% decreases, p = 0.044 and 0.036, respec-
tively) suggesting that 99mTc-maraciclatide may be useful for
determining early treatment response. A difference in percent-
age change in 99mTc-maraciclatide uptake (SPECT T:M
ratio) was also seen between lesions that showed an
increase in CT HU and those that showed a decrease
(p = 0.016), and the inverse correlation also suggests
that 99mTc-maraciclatide activity may be related to un-
derlying changes in the bone microenvironment follow-
ing treatment, including changes in osteoclast activity.
These data are supported by the previously mentioned
preclinical study of osteolytic metastases in a transgenic
mouse model that showed reductions in uptake of 64Cu-
CB-TE2A-c(RGDyK) following treatment with an oste-
oclast inhibitor, the bisphosphonate zolendronate [9].
Human skeletal diseases that are known to exhibit great-
er osteoclast activity than PCa, such as multiple
Fig. 3 Fused axial SPECT/CT
image (top left), CT image (bot-
tom left), axial SPECT image (top
right) and coronal maximum
intensity image (bottom left) show
a sternal lesion in a patient with a
treatment response: a before
treatment (T:N ratio 8.66, T:M
ratio 11.97, HU= 155), b
12 weeks after starting treatment
(T:N ratio 4.42, T:M ratio 5.18,
HU= 413)
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myeloma [16] or periprosthetic osteolysis [17], would
provide relevant clinical models to further test this
hypothesis.
The main limitation of this study is that we had no direct
measurement of the proportion of uptake of 99mTc-
maraciclatide that was specific to osteoclast activity or what
degree of uptake may have been tumour-specific or endothe-
lial/angiogenesis-specific. Indeed it is known that PCa cell
lines derived from bone metastases express the αvβ3 integrin
[18] and we cannot exclude an effect on baseline measure-
ments from previous therapy in the subset of our patients
recruited with PD following previous treatment.
Nevertheless, the inverse correlations we observed with CT
density measured in HUs that is known to be related to oste-
oclastic and osteoblastic phenotypes before treatment and, in
particular, the changes with treatment, support the hypothesis
that 99mTc-maraciclatide uptake is related to osteoclast activity
through targeting theαvβ3 integrin. Planar T:N and T:M ratios
are prone to greater measurement error than SPECT ratios but
the planar ratios are nevertheless of interest in this first study
of 99mTc-maraciclatide imaging of skeletal metastases in PCa
in providing a quantitative description of uptake and a com-
parator for future studies. Secondly, abiraterone is not known
to have a direct anti-osteoclastic effect and it is likely that the
changes in 99mTc-maraciclatide uptake we observed in bone
metastases were in part the result of a secondary downstream
reduction in osteoclast activity following the antitumour ac-
tion of abiraterone caused by inhibition of androgen synthesis
[19].
Conclusions
99mTc-maraciclatide accumulates in bone metastases from
PCa in keeping with increased expression of αvβ3 integrin,
and shows an inverse correlation with CT density, suggesting
a relationship with osteoclast activity. In addition, changes in
99mTc-maraciclatide uptake after 12 weeks of systemic thera-
py with abiraterone differ between patients with subsequent
PD and non-PD and this may therefore be a potential method
for predicting clinical response that deserves further study.
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